The FDA approved Revolution Medicines’ daraxonrasib (Rasonque), the first RAS inhibitor cleared for pancreatic ductal adenocarcinoma, targeting metastatic patients with disease progression after chemotherapy. The approval follows priority review and is positioned as an option for a population with limited subsequent-treatment choices. In the supporting clinical program, daraxonrasib improved median overall survival to 13.2 months versus 6.6–6.7 months with chemotherapy in the relevant comparative cohort reported earlier in 2026. The label supports a regimen that is taken orally on a twice-daily basis. Analysts and clinicians framed the clearance as a potential step-change because it directly addresses a genetic driver in a tumor type that has historically resisted targeted therapy. Revolution Medicines said it is moving forward on next steps for launch readiness.